US/UK/Canada

Share

Pick a time period -
Tags ( Active)

InDex Pharmaceuticals Holding AB (publ) year-end report 2023

Full focus on closing phase III programPeriod October – December 2023 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –107.9 (–58.2) million · Result after tax amounted to SEK –105.5 (–56.3) million, corresponding to SEK –0.20 per share (–0.11) before and after dilution · Cash flow from operating activities amounted to SEK –47.0 (–34.2) million Period January – December 2023 · Net sales amounted to SEK 97.5 (0.0) million · Operating result amounted to SEK –107.4 (–103.2) million · Result after tax amounted to SEK –95.3 (–100.3)

InDex Pharmaceuticals Holding AB (publ) year-end report 2022

PK Study fully recruited”Given the dose selection in Q4 2023 our near-term focus remains on increasing the speed of site and patient recruitment and we look forward to seeing the results of our action plan bear fruit in 2023”, said Jenny Sundqvist, CEO of InDex Pharmaceuticals. Period October – December 2022 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –58.2 (–22.7) million · Result after tax amounted to SEK –56.3 (–22.8) million, corresponding to SEK –0.11 per share (–0.04) before and after dilution · Cash flow from operating activities

InDex Pharmaceuticals Holding AB (publ) year-end report 2021

First patient enrolled in the phase III study CONCLUDE“At the end of November, the first patient was enrolled in the phase III study CONCLUDE and I am proud that we have achieved this important milestone on the way towards market approval,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period October – December 2021 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –22.7 (–10.1) million · Result after tax amounted to SEK –22.8 (–10.1) million, corresponding to SEK –0.04 per share (–0.04) before and after dilution · Cash flow from operating

InDex Pharmaceuticals Holding AB (publ) year-end report 2020

Financing secured for phase III development of cobitolimod“With the equity financing secured until the next pivotal read-out of clinical data, it feels very inspiring to now advance cobitolimod into phase III, which is the final stage of development before application for market approval,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period October – December 2020 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –10.1 (–25.6) million · Result after tax amounted to SEK –10.1 (–25.6) million, corresponding to SEK –0.04 per share (–0.11) before

InDex Pharmaceuticals Holding AB (publ) year-end report 2019

Cobitolimod’s outstanding combination of efficacy and safety confirmed in in-depth analysis“The robustness and consistency of the CONDUCT results support our strategy to move cobitolimod forward in development and our phase III preparations are continuing according to plan,” says Peter Zerhouni, CEO of InDex Pharmaceuticals.    Period October – December 2019 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –25.6 (–22.3) million · Result after tax amounted to SEK –25.6 (–22.3) million, corresponding to SEK –0.29 per share (–0.33) before and

InDex Pharmaceuticals Holding AB (publ) year end report 2018

Continued focus on the patient recruitment for the CONDUCT studyPeriod October – December 2018 ·  Revenues amounted to SEK 0.6 (0.0) million ·  Operating result amounted to SEK –22.5 (–22.6) million ·  Result after tax amounted to SEK –22.5 (–22.4) million, corresponding to SEK –0.33 per share (–0.36) before and after dilution ·  Cash flow from operating activities amounted to SEK –20.9 (–14.1) million  Period January – December 2018  ·  Revenues amounted to SEK 0.7 (0.1) million ·  Operating result amounted to SEK –82.4 (–73.3) million ·  Result after tax

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe